New therapeutic strategies in the treatment of hepatitis B virus infection

Bibliography

• ZUCKERMAN A, THOMAS HC (Eds.): Viral hepatitis: sci-entific basis and clinical management (First edition). Churchill Livingstone, London (1993).
   Google Scholar
• BEASLEY R: Hepatitis B virus-the major etiology of he-patocellular carcinoma. Cancer (1988) 61:1942–1956.
   PubMed Web of Science ®Google Scholar
• BEASLEY R, UN C, HVVANG L, CHEIN C: Hepatocellular carcinoma and hepatitis B virus. Lancet (1981) 2:1129–1133.
   PubMed Web of Science ®Google Scholar
• GANEM D: Persistent infection of humans with hepati-tis B virus: mechanisms and consequences. Review In-fect. Dis. (1982) 4:1026–1047.
   PubMedGoogle Scholar
• OBATA H, HAYASHI N, MOTOIKE Y: A propsective study of development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B infection. mt. J. Cancer (1980) 25:741.
   PubMed Web of Science ®Google Scholar
• CHANG MH, CHEN CJ, LAI SD et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocel-lular carcinoma in children. New Engl. J. Med (1997) 336:1855–1859.
   PubMed Web of Science ®Google Scholar
• CARMAN WF: The clinical significance of surface anti-gen variants of hepatitis B virus. J. Viral Hepatitis (1997) 4 (1) :11–20.
   PubMedGoogle Scholar
• HOOFNAGLE JH, DI BISCELGIE AM: Drug Therapy: The treatment of chronic viral hepatitis. New Engl. J. Med. (1997) 336:347–356.
   PubMed Web of Science ®Google Scholar
• ISKIKAWA T, GANEM D: The pre-S domain of the large envelope protein determines host range in avian hepatitis B viruses. Proc. Natl. Acad. Sci. USA (1995) 92:6259–6263.
   PubMed Web of Science ®Google Scholar
• NEURATH A, KENT S, STRICK N, PARKER K: Identifica-tion and chemical synthesis of a host cell receptor-binding site on hepatitis B virus. Cell (1986) 46(3):429–436.
   PubMed Web of Science ®Google Scholar
• PONTISSO P, PETIT MA, BANKOWSKI MJ, PEEPLES ME: Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymer-ized human serum albumin, for the pre-S2 region. J. Vi-rol. (1989) 63:1981–1988.
   PubMed Web of Science ®Google Scholar
• KLINGMULLER U, SCHALLER H: Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J. Virol. (1993) 67 (12):7414–7422.
   PubMed Web of Science ®Google Scholar
• BRUNS M, MISKA S, CHASSOT S, H WILL: Enhancement of hepatitis B virus infection by noninfectious subviral particles. J. Virol. (1998) 72(2):1462–1468.
   PubMed Web of Science ®Google Scholar
• KOCK J, SCHLICHT H: Analysis of the earliest steps of hepadnavirus replication: genome repair after infec-tious entry into hepatocytes does not depend on viral polymerase activity. J. Virol. (1993) 67(8):4867–4874.
   PubMed Web of Science ®Google Scholar
• TUTTLEMAN JS, POURCEL C, SUMMERS J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell (1986) 47:451–460.
   PubMed Web of Science ®Google Scholar
• TAVIS J: The replication strategy of the hepadnavi-ruses. Viral Hepatitis Rev. (1996) 2(3):205–218.
   Google Scholar
• NASSAL M, SCHALLER H: Hepatitis B virus replication-an update. J. Viral Hepatitis (1996) 3(5):217–226.
   PubMed Web of Science ®Google Scholar
• CIVITICO GM, LOCARNINI SA: The half-life of duck hepatitis B virus supercoiled DNA in congenitally in-fected primary hepatocyte cultures. Virology (1994) 293 (1) :81–89.
   Google Scholar
• GANEM D, VARMUS H: The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. (1987) 56:651–693.
   PubMed Web of Science ®Google Scholar
• WANG GH, SEEGER C: The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell (1992) 71:663–670.
   PubMed Web of Science ®Google Scholar
• WANG GH, ZOULIM F, LEBER E H, KITSON J, SEEGER C: Role of RNA in enzymatic activity of the reverse tran-scriptase of hepatitis B viruses. J. Vim]: (1994) 68:8437–8442.
   Web of Science ®Google Scholar
• NASSAL M, RIEGER A: A bulged region of the hepatitis Bvirus RNA encapsidation signal contains the replica-tion origin for discontinuous first-strand DNA synthe-sis. J. Virol. (1996) 70:2764–2773.
   PubMed Web of Science ®Google Scholar
• WEIZSACKER VF, WETLAND S, KOCK J, OFFENSPERGER, W-B, OFFENSPERGER S, MORADPOUR D, BLUM H: Gene therapy for chronic viral hepatitis : ribozymes, an-tisense oligonucleotides, and dominant negative mu-tants. Hepatology (1997) 26(2) :251–255.
   PubMedGoogle Scholar
• COHEN J: Antisense oligodeoxynucleotides as antiviral agents. Antiviral Res. (1991)16:121–123.
   PubMed Web of Science ®Google Scholar
• OFFENSPERGER, W-B, OFFENSPERGER S, WALTER E, TEUBNER K, IGLOI G, BLUM HE, GEROK W: In vivo inhi-bition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBOJ (1993) 12 (3):1257–1262.
   PubMed Web of Science ®Google Scholar
• WANDS J, GEISSLER M, PUTLITS J et al.: Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. J. Castro. Hepatol. (1997) 12:S354–369.
   Web of Science ®Google Scholar
• KORBA BE, GERIN J: Antisense oligonucleotides are ef-fective inhibitors of hepatitis B virus replication in vi-tro. Antiviral Res. (1995) 28(3)225–242.
   Google Scholar
• WU J, GERBER M: The inhibitory effects of antisense RNA on hepatitis B virus surface antigen synthesis. J. Gen. Virol. (1997) 78:641–647.
   PubMed Web of Science ®Google Scholar
• WU G, WU C: Specific inhibition of hepatitis B virus gene expression in vitro by targeted antisense oligode-oxynucleotides. J. Biol. Chem. (1992) 267(12) :436–439.
   Google Scholar
• BLUM HE, GALUN E., LIANG TJ, VON WEIZSACKER F, WANDS JR: Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus rep-lication. J. Virol. (1991) 65(4):1836–1842.
   PubMed Web of Science ®Google Scholar
• ZHIQIANG Y, YONGXING Z, XIEMI F, CHONGXIN C, JUN G: In vivo inhibition of hepatitis B viral gene expres-sion by antisense phosphorothioate oligodeoxynu-cleotides in athymic nude mice. J. Viral Hepatitis (1996) 3:19–22.
   PubMed Web of Science ®Google Scholar
• SONI PN, BROEN D, SAFFIE R, SAVAGE K, MOORED, GRE-GORIADIS G, DUSHEIKO GM: Biodistribution, stability, and antiviral efficacy of liposome-entrapped phos-phothiorate anti-sense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B vi-rus infection. Hepatology (1998) 28(5) :1402–1410.
   PubMed Web of Science ®Google Scholar
• BARTHOLOMEW RM, CARMICHEAL EP, FINDEIS MA, WU CH, WU GY: Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J. Vi-ral Hepatitis (1995) 2(6):273–278.
   PubMed Web of Science ®Google Scholar
• TUNG F, BOWEN S: Targeted inhibition of hepatitis B vi-rus gene expression: a gene therapy approach. Front. Biosci. (1998) 3:A11–A15.
   PubMedGoogle Scholar
• JI W, ST C: Inhibition of hepatitis B virus by retroviral vectors expressing anti-sense RNA. J. Viral Hepatitis (1997) 4(3):167–173.
   PubMed Web of Science ®Google Scholar
• CECH T: The chemistry of self-splicing RNA and RNA enzymes. Science (1987) 236:1532–1539.
   PubMed Web of Science ®Google Scholar
• HASELOFF J, GERLACH W: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (1988) 334:585–591.
   PubMed Web of Science ®Google Scholar
• WELCH P, TRITZ R, YET S, BARBER J, YU M: Intracellular application of hairpin ribozyme genes against hepati-tis B virus. Gene Ther. (1997) 4(7):736–743.
   PubMed Web of Science ®Google Scholar
• ASAHINA Y, ITO Y, WU CH, WU GY: DNA ribonucleases that are active against intracellular hepatitis B viral RNA targets. Hepatology (1998) 28 (2) :547–554.
   PubMed Web of Science ®Google Scholar
• SCAGLIONI PP, MELEGARI M, WANDS JR: Characteriza-tion of hepatitis B virus core mutants that inhibit viral replication. Virology (1994) 205:112–120.
   PubMed Web of Science ®Google Scholar
• SCAGLIONI P, MELEGARI M, TAKAHASHI M, CHOWD-HURY J, WANDS J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. He-patology (1996) 24(5):1010–1017.
   Google Scholar
• MILCH DR: Immune response to the hepatitis B virus: infection, animal models, vaccination. Viral Hepatitis Rev. (1997) 3(2):63–103.
   Google Scholar
• WALLACE L, CARMAN WF: Surface gene variation of HBV: scientific and medical relevance. Viral Hepatitis Rev. (1997) 3(1):5–16.
   Google Scholar
• MICHEL M: Prospects for active immunotherapies for hepatitis B virus chronic carriers. Res. Vim]. (1997) 148:95–99.
   PubMedGoogle Scholar
• SENTURK H, TABAK M, AKTOGAN M et al.: Therapeutic vaccination with a pre-52 containing vaccine in chronic hepatitis B: a promising approach. Hepatology (1998) 28(4):A1701.
   Google Scholar
• LACAILLE F, POL S: Specific vaccine therapy of chronic hepatitis B in children. Hepatology (1998) 28 (4):A2253.
   Google Scholar
• POL S, DRISS I, COULLIN I et al.: A controlled study of anti-HBV vaccine therapy in chronic hepatitis B infec-tion. Hepatology (1998) 28(4) :A1301.
   Google Scholar
• CHOW Y-H, CHIANG B-L, LEE Y-L et al.: Development of Thl and Th2 populations and the nature of immune re-sponse to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol. (1998) 160:1320–1329.
   PubMed Web of Science ®Google Scholar
• CHIEN RN, L Y, CHEN TC, YEH CT, SHEEN IS: Efficacy ofthymosin alpha 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology (1998) 27 (5) :1383–1387.
   PubMed Web of Science ®Google Scholar
• MUTCHNICK MG, LINDSAY K, SCHIFF, E, CUMMINGO G, APPLEMAN H: Thymosin a 1 treatment of chronic hepa-titis B: a multicenter placebo-controlled double blind study. Gastroenterology (1995) 108:A1127.
   Web of Science ®Google Scholar
• MUTCHNICK MG, APPLEMAN HD, CHUNG HT et al.: Thy-mosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology (1991) 14:409–415.
   PubMed Web of Science ®Google Scholar
• SHAW T, LOCARNINI SA: Hepatic purine and pyrimid-ine metabolism: implications for antiviral chemother-apy of viral hepatitis. Liver (1995) 15:169–184.
   PubMedGoogle Scholar
• LUSCOMBE CA, LOCARNINI SA: The mechanism of ac-tion of antiviral agents in chronic hepatitis B. Viral Hepatitis Rev. (1996) 1(3):1–35.
   Google Scholar
• BOYD M, SAFRIN S, KERN E: Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. (1993) 4:3–11.
   Web of Science ®Google Scholar
• VERE HODGE R: Review: antiviral portait series number 3. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to pen-ciclovir. Antiviral Chem. Chemother. (1993) 4:67–84.
   Google Scholar
• TSIQUAYE K, SLOMKA M, MAUNG M: Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J. Med. Vim]. (1994) 42(3):306–310.
   PubMed Web of Science ®Google Scholar
• SHAW T, AMOR P, CIVITICO G, BOYD M, LOCARNINI S: In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. (1994) 38(4)719–723.
   Google Scholar
• NICHOL A, LOCARNINI SA: Present and future direc-tions in the treatment of chronic hepatitis B infection. Hepatol. (1997) 12:843–854.
   Web of Science ®Google Scholar
• SHAW T, MOK S, LOCARNINI S: Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibi-tion of HBV replication by penciclovir. Hepatology (1996) 24(5):996–1002.
   PubMed Web of Science ®Google Scholar
• MOK S, SHAW T, LOCARNINI S: Preferential inhibitionof human hepatitis B virus (HBV) DNA polymerase by the R (-) enantiomer of penciclovir triphosphate. Anti-micob. Agents Chemother. (1995):A746.
   Google Scholar
• EARNSHAW D, BACON T, DARLISON S, EDMONDS K, PERKINS R, VERE HOD GE R: Penciclovir: mode of antivi-ral action of penciclovir in MRC-5 cells infected with herpes simplex virus (HSV 1), HSV-2 and varicella zos-ter virus. Antimicrob. Agents Chemother. (1992) 36:2747–2757.
   PubMed Web of Science ®Google Scholar
• LIN E, LUSCOMBE C, WANG Y, SHAW T, LOCARNINI S:The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. (1996) 40(2) 413–418.
   PubMed Web of Science ®Google Scholar
• LOCARNINI S, LIN E, LUSCOMBE C et al: Penciclovir: anovel nucleoside analogue with potent activity against duck hepatitis B virus in vitro. Antiviral Res. (1995) 26:A242.
   Google Scholar
• LEE B, LUO W, SUZUKI, S, ROBINS M, TYRRELL D: In vitroand in vivo comparison of the abilities of purine and pyrimidine 2', 3'-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob. Agents Chemother. (1989) 33 (3):36–339.
   Google Scholar
• TSIQUAYE K, SUTTON D, MAUNG M et al.: Antiviral ac-tivities and pharmacokinetics of penciclovir and fam-ciclovir in pekin ducks chronically infected with duck hepatitis B virus. Antiviral Chem. Chemother. (1996) 7:153–159.
   Web of Science ®Google Scholar
• WANG Y, BOWDEN S, SHAW T, CIVITICO G, CHAN Y, QIAO M, LOCARNINI S: Inhibition of duck hepatitis B vi-rus replication in vivo by the nucleoside analogue gan-ciclovir(9[2-hydroxy-1- (hydroxymethyl)ethoxymethyl] guanine). Antiviral Chem. Chemother. (1991) 2(2):107–114.
   Google Scholar
• WU TT, COATES L, ALDRICH CE, SUMMERS J, MASON WS: In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an in-tracellular pathway. Virology (1990) 175:255–261.
   PubMed Web of Science ®Google Scholar
• AYE TT, BARTHOLOMEUSZ A, SHAW T et al.: Hepatitis B virus polymerase mutations during famciclovir ther-apy in patients following liver transplantation. Hepa-tology (1996) 24:285A.
   Google Scholar
• KRUGER M, TILMAN H, TRAUTWEIN C et al.: Treatment ofhepatitis B virus re-infection after liver transplanta-tion with famciclovir. Hepatology (1994) 20:A130.
   Web of Science ®Google Scholar
• BOKER K, RINGE B, KRUGER M, PICHLMAYR R, MANNS M:Prostaglandin E plus famciclovir-a new concept for the treatment of severe hepatitis B after liver trans-plantation. Transplantation (1994) 57 (12):1706–1708.
   PubMed Web of Science ®Google Scholar
• MAIN J, BROWN L, HOWELLS C et al.: A double-blind,placebo-controlled study to assess the effect of famci-clovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepatitis (1996) 3:211–215.
   PubMed Web of Science ®Google Scholar
• NEUHAUS P, MANNUS M, ATKINSON G: Safety and effi-cacy of famciclovir for the treatment of recurrent hepatitis B infection in liver transplant recipients. He-patology (1997) 26(4):A528.
   Google Scholar
• TREPO C, JEZEK P, ATKINSON GF, BOON RJ: Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study. Hepatology (1996) 24:A188.
   Google Scholar
• RABINOVITZ M, DODSON F, RAKELA J: Famciclovir for recurrent hepatitis B (HBV) infection after liver trans-plantation (OLTx). Hepatology (1996) 24 (4):A624.
   Web of Science ®Google Scholar
• BENNER K, ROSEN H, FLORA K: Famciclovir treatmentof decompensated HBV cirrhosis. Hepatology (1996) 24 (4):A622.
   Web of Science ®Google Scholar
• BARTHOLOMEUSZ A, GROENEN L, LOCARNINI S: Clinicalexperience with famciclovir against hepatitis B virus. Intervirology (1997) 40 (5-6):337–342.
   PubMed Web of Science ®Google Scholar
• DE MAN R, BARTHOLOMEUSZ A, LOCARNINI S, NIESTERSH, ZONDERVAN P: The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: primary famciclovir resistance fol-lowed by a lethal hepatitis during acquired lamivudine resistance. Hepatol (1997) 26(1):77.
   Google Scholar
• TILLMAN H, TRAUTWEIN C, KRUGER M et al.: Inhibition of hepatitis B virus replication with lamivudine in pa-tients previously treated with famciclovir after liver transplantation. J. Hepatol. (1997) 26(1)153.
   Google Scholar
• LOCARNINI S et al.: The emergence of famciclovir resis-tant mutations in the hepatitis B virus polymerase dur-ing therapy in patients following liver transplantation. Hepatology (1997) 26 (4):A958.
   Web of Science ®Google Scholar
• TILMANN H, TRAUTWEIN C, BOCK T et al: Response and mutations in patients sequentially treated with lami-vudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology (1997) 24 (6):A1202.
   Google Scholar
• LAI CL, YEUN MF, CHENG CC, WONG WM, CHENG TK, LAI YP: An open comparative study of lamivudine and fam-ciclovir in the treatment of chronic hepatitis B infec-tion. Hepatology (1998) 28(4):A1311.
   Google Scholar
• NAESENS L, SNOECK R, ANDREI G, BALZARINI J, NEYTS J, DE CLERQ E: HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem. Che-mother. (1997) 8(0:1–23.
   Google Scholar
• DE CLERCQ E: Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkyl-purines and -pyrimidines. Biochemical Pharmacology (1991) 42(5):963–972.
   PubMedGoogle Scholar
• HEIJTINK R, DE WILDE G, KRUNING J eta].: Inhibitory ef-fect of 9- (2-phosphonoyl-methoxyethyl) -adenine (PMEA) on human and duck hepatitis B virus infec-tion. Antiviral Res. (1993) 21:141–153.
   Google Scholar
• HEIJTINK R, KRUINING J, DE WILDE G, BALZARINI J, DE CLERCQ E, SCHALM S: Inhibitory effects of acyclic nu-cleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. (1994) 38(9)2180–2182.
   Google Scholar
• YOKOTA T, KONNO K, SHIGETA S, HOLY A, BALZARINI J, DE CLERQ E: Inhibitory effects of acyclic nucleoside phosphonate analogues on hepatitis B virus DNA syn-thesis in HB Gil cells. Antiviral Chem. Chemother. (1994) 5:57–63.
   Web of Science ®Google Scholar
• XIONG X, FLORES C, GIBBS C, TOOLE I: Lack of cross re-sistance to PMEA for human hepatitis B DNA po-lymerase which expresses lamivudine resistance codons. Hepatology (1997) 26 (4):A1211.
   Web of Science ®Google Scholar
• YOKOTA T, MOCHIZUKI S, KONNO K, MORI S, SHIGETA S, DE CLERCQ E: Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthe-sis. Antimicrob. Agents Chemother. (1991) 35(2)394–397.
   Google Scholar
• BALZARINI J, HOLY A, JINDRICH J et al.: 9-[(2RS)-3-fluoro-2- phosphonylmethoxypropyl] de-rivatives of purines: a class of highly selectiveantiretroviral agents in vitro and in vivo. Proc. Nati Acad. ScL USA (1991) 88(10:4961–4965.
   PubMedGoogle Scholar
• CALIO R, VILLANI N, BALESTRA J et al.: Enhancement of natural killer activity and interferon induction by dif-ferent acyclic nucleoside phosphonates. Antiviral Res. (1994) 23:77–89.
   PubMed Web of Science ®Google Scholar
• GILSON R, CHOPRA K, MURRAY-LYON I et al.: A placebo controlled Phase I/II study of adefovir dipivoxil (Bis-POM PMEA) in patients with chronic hepatitis B infec-tion. Hepatology (1996) 24(4):A620.
   PubMed Web of Science ®Google Scholar
• NICOLL A, COLLEDGE D, WANG Y et al.: PMEA, an acyclic phosphonate nucleoside analogue with activity against duck hepatitis B virus in vitro. Hepatology (1996) 24(4):A375.
   Web of Science ®Google Scholar
• HEATHCOTE EJ, JEFFERS L, WRIGHT T et al. Loss of se-rum HBV DNA and HBeAg seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled Phase II studies. Hepatology (1998) 28(4) A620
   PubMedGoogle Scholar
• FIELD A, TUOMARI A, MCGEEVER-RUBIN B et al.:(+I +(la, 20, 3a)-9[2,3-bis(hydroxymethyl) cyclobu-tyll guanine [(+/-)-BHCG or SQ 33,054]: a potent and se-lective inhibitor of herpesviruses. Antiviral Res. (1990) 13 (1):41–52.
   PubMed Web of Science ®Google Scholar
• HUNG L, BRUMBAUGH A, BHATIA G et al.: Effects of pu-rine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and 11IV-1 in cell culture. J. Med. Virol. (1991) 35(3):180–186.
   PubMed Web of Science ®Google Scholar
• YAMANAKA G, TUOMARI A, HAGEN M eta].: Selective ac-tivity and cellular pharmacology of (1R- 1 cc, 20, 3a)-9[2,3-bis(hydroxymethyl) cyclobutyll guanine in herpesvirus-infected cells. MoL PharmacoL (1991) 40(3)446–453.
   Google Scholar
• TERRY B, CIANCI C, HAGEN M: Inhibition of herpes sim-plex virus Type 1 DNA polymerase by (1R-la, 28, 3a)-9[2,3-bis(hydroxymethyl) cyclobutyll guanine. Mol. Pharmacol. (1991) 40(4) 591–596.
   PubMed Web of Science ®Google Scholar
• BLOOMER J, CHAN R, SHERMAN M, INGRAHAM P, De HERTOGH D: A preliminary study of lobucavir for chronic hepatitis B. Hepatology (1991) 26(4) :A1199.
   Google Scholar
• ZOULIM F, TREPO C: Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on outcome of therapy. J. Hepa-tol. (1998) 29:151–168.
   PubMed Web of Science ®Google Scholar
• DOONG S, TSAI C, SCHINAZI R, LIOTTA D, CHENG Y: In-hibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues. Proc. Natl. Acad. ScL USA (1991) 88(19):8495–8499.
   PubMed Web of Science ®Google Scholar
• CHANG C, DOONG S, ZHOU J et al.: Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2', 3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. (1991) 267(20)13938–13942.
   Google Scholar
• SEVERINI A, LIU X, WILSON J, TYRRELL D Mechanism of inhibition of duck hepatitis B virus polymerase by 3'-dideoxy- 3'-thiacytidine. Antimicrob. Agents Chemother. (1995) 39(7):1430–1435.
   PubMed Web of Science ®Google Scholar
• FURMAN P, PAINTER G: The role of absolute configura-tion in the anti-HIV and anti-HBV activity of nucleoside analogues. International Antiviral. News (1995) 3(5)74–77.
   Google Scholar
• CHIEN-NENG C, DOONG S-L, ZHOU JH et al: Deoxycyti-dine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-deoxy-3'-thiacytidine in the inhibi-tion of hepatitis B virus replication. J. Biol. Chem. (1992) 267(20)13938–13942.
   Google Scholar
• SCHINAZI R, GOSSELIN G, FARAJ A etal.: Pure nucleoside enantiomers of 13-2', 3'- dideoxycytidine analogs are se-lective inhibitors of hepatitis B virus in vitro. Antimi-crob. Agents Chemother. (1994) 38(9):2172–2174.
   Google Scholar
• UN T, LUO M, LIU M, PAI S, DUTSCHMAN G, CHENG Y: Antiviral activity of 2', 3'-dideoxy-134-5-fluorocytidine (13-L-FddC) and 2', 3'-dideoxy-13-L-cytidine (13-L-ddC) against hepatitis B virus and human immunodefi-ciency virus Type 1 in vitro. Biochem. Pharmacol. (1994) 47(2):171–174.
   PubMed Web of Science ®Google Scholar
• LAIC, CHIEN R, LEUNG N, CHANG T, GUAN R, TAI D et al: A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New Engl. J. Med. (1998) 339(2):61–68.
   PubMed Web of Science ®Google Scholar
• DIENSTAG J, PERRILLO R, SCHIFF E, BARTHOLOMEW M, VICARY C, RUBIN M: A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl. J. Med. (1995) 333(25):1657–1661.
   PubMed Web of Science ®Google Scholar
• DIENSTAG J, SCHIFF E, MITCHELL M et al: Extended lamivudine retreatment for chronic hepatitis B. Hepa-tology (1996) 24(4):A245.
   Web of Science ®Google Scholar
• HOONKOOP P, DE MAN R, NEISTERS H, SCHALM H: Lami-vudine withdrawal flares successfully treated with lamivudine in patients with chronic hepatitis B. Hepa-tology (1996) 26(4):A1204.
   Web of Science ®Google Scholar
• LAU D T-Y, DOO E, GAHNY M et al: Lamivudine for chronic hepatitis B with typical and atypical serology. Hepatology (1997) 26(4):A1203.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ J, PAKRASI A, HOLLIS P, GOLDSTEIN L, BUS-SUTTI R: Efficacy of lamivudine for prophylaxis and treatment of hepatitis B in liver transplant patients. Hepatology (1996) 24 (4):A222.
   Web of Science ®Google Scholar
• PERRILLO R, RAKELA J, MARTIN P, LEVY G, SCHIFF E, WRIGHT J: Lamivudine for hepatitis B after liver trans-plantation (OLT). Hepatology (1996) 24(4):A223.
   Web of Science ®Google Scholar
• PERILLO R, RAKELA J, MARTIN P et al.: Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation. Hepatology (1997) 26(4):A526.
   Web of Science ®Google Scholar
• LAI CL, LIAW YF, LEUNG N et al.: A 12 month course of lamivudine (100 mg od) therapy improves liver histol-ogy: results of a placebo controlled multicentre study in Asia. J. Hepatol (1997) 26(0:79.
   Google Scholar
• LAI C, LIAW Y, LEUNG N et al.: Genotypic resistance to lamivudine in a prospective placebo-controlled multi-centre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters. Hepatology (1997) 26(4):A522.
   Web of Science ®Google Scholar
• BARTHOLOMEW MM, JANSEN RW, JEFFERS LJ et al.: Hepatitis-B-virus resistance to lamivudine given for re-current infection after orthotopic liver transplanta-tion. Lancet (1997) 349:20–22.
   PubMed Web of Science ®Google Scholar
• LING R, MUTIMER D, AHMED M et al.: Selection of muta-tions in the hepatitis B virus polymerase during ther-apy of transplant recipients with lamivudine. Hepatology (1996) 24:711–713
   PubMed Web of Science ®Google Scholar
• NAOUMOV NV, CHOKSHI S, SMITH H, WILLIAMS R: Emergence and characterisation of lamivudine resis-tant hepatitis B virus variant. Hepatology (1996) 24:282A
   Google Scholar
• TILLMAN HL, TRAUTWEIN C, KRUGER M et al: Inhibition of hepatitis B virus replication with lamivudine in pa-tients previously treated with famciclovir after liver transplantation. J. Hepatol (1997) 26 (1):153.
   Google Scholar
• TIPPLES GA, MA MM, FISCHER KP, BAIN VG, KNETEMAN NM, TYRRELL DL Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology (1996) 24:714–717
   PubMed Web of Science ®Google Scholar
• NAUMOV N, CHOKHSI S, SMITH H, WILLIAMS R Emer-gence of lamivudine resistant hepatitis B virus variant. Hepatology (1996) 24(4):A621.
   Web of Science ®Google Scholar
• GUTFREUND K, FISCHER K, TIPPLES G et al.: Late break-through of HBV viremia with lamivudine as a single agent for prevention of graft reinfection in liver trans-plantation for cirrhosis secondary to hepatitis B. Hepa-tology (1996) 24(4):A634.
   Web of Science ®Google Scholar
• CHANG C, DOONG S, ZHOU J et al.: Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2', 3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. (1992) 267(20)13938–13942.
   Google Scholar
• FISCHER K, CHENG Y-C, TYRRELL D: The mutation in duck hepatitis B polymerase which confers resistance to lamivudine (13-L-(-)- thiacytidine, 3TC) also confers cross-resistance to IA- dideoxy-5-fluorocytidine. He-patology (1996) 24(4):A246.
   Google Scholar
• CHUNG K, TIANWEI M, SHANMUGANATHGAN K et al.: Use of 2'-fluoro-5-methy1-134.. arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. (1995) 39 (4) :979–981.
   Google Scholar
• PAI S, LIU S-H, ZHU Y-L, CHU C, CHIENG C: Inhibition of hepatitis B virus bu a novel L-nucleoside 2'-fluoro-5-methyl-13-L-arabinofuranosyl uracil. Anti-micob. Agents Chermotherap. (1996) 40(2):380–386.
   PubMed Web of Science ®Google Scholar
• WITCHER J, BOUDINOT F, BALDWIN B et al.: Pharma-cokinetics of 1-(2-fluoro-5-methyl-134, arabinofurano-syl) uracil in woodchucks. Antimicrob. Agents Chemother. (1997) 41(10):2184–2187.
   PubMedGoogle Scholar
• AGUESSE S, BOREL C, CHEVALIER M et al.: Inhibitory ef-fect of 2'-fluoro-5-methyl-13-L-arabinosyluracil FMAU), a novel L-nucleoside analog, on duck hepatitis B virus replication. Hepatology (1996) 24(4):A372.
   Web of Science ®Google Scholar
• BARTHOLMEUSZ A, SCHINAZI RF, LOCARNINI SA: Sig-nificance of mutations in the hepatitis B virus po-lymerase selected by nucleoside analogues and implications for controlling chronic disease. Viral Hepatitis Rev. (1998) 3 (4) :167–187.
   Google Scholar
• COLLEDGE D, LOCARNINI S, SHAW T: Synergistic inhibi-tion of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology (1997) 26:216–225.
   PubMed Web of Science ®Google Scholar
• COREY L, HOLMES KK: Therapy for human immunode-ficiency virus infection-what have we learned? New Engl. J. Med. (1996) 335:1142–1144.
   Google Scholar
• DE JONG MC, BOUCHER CAB, GALASSO GJ et al.: Consen-sus symposium on combination therapy. Science (1995) 29:5–29.
   Google Scholar
• LARDEN BA, KEMP SD, HARRIGAN PR: Potential mecha-nism for sustained antiviral efficacy of AZT-3TC com-bination therapy. Science (1995) 269:696-699. Joseph Torresit & Stephen Locarnini fAuthor for correspondence Victorian Infectious Diseases Service c/o Post Office, The Royal Melbourne Hospital Parkville, Victoria, Australia, 3050 Tel.: +61 3 9342 7212; Fax: +61 3 9342 7277; Email: [email protected]
   Google Scholar